Passing away of an independent non-executive director and change in composition of board committees
Filed with HKEX · Stock code 1548 · · 2 pages · English
The board (the “Board”) of directors (the “Directors”) of Genscript Biotech Corporation (the “Company”) hereby announces with deepest sorrow that Dr. Alphonse Galdes (“Dr. Galdes”), an independent non-executive Director and a member of the audit committee (the “Audit Committee”) of the Company, was confirmed passing away on 13 September 2026 (Hong Kong Time). Dr. Galdes had served the Board as an
Genscript Biotech Corporation on 6ix
Earlier from Genscript Biotech
- Interim report 2026
- Next Day Disclosure Return
- Completion of placing of new shares under the general mandate
- GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
- GenScript Sets New Benchmark for Responsible Biotech Leadership with 2025 ESG Report
Later from Genscript Biotech
- List of directors and their role and function
- Announcement pursuant to rule 13.10 of the listing rules
- Change in board lot size
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement: legend announces preliminary sales for CARVYKTI for the quarter ended 30 September 2026
Follow Genscript Biotech into a list and get an email when it puts out news.
Follow Genscript Biotech